TY-JUR T1 - 哮喘和冠状病毒疾病2019年风险：系统评价和META分析JF - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003 - 2101209 AU - Sunjaya，Anthony P. Au - Allida，sabine m. au - di tanna，伟大的leuca au - jenkins，christine r. y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/07/29/13993003.01209-2021摘要N2 - 背景单个案例系列和队列研究报告了对来自Covid-19的哮喘哮喘患者的脆弱性和风险的漏洞产生冲突的结果。研究问题是哮喘的人，患有较高的感染，住院或较差的临床来自Covid-19的结果？方法，基于五个主要数据库的系统审查和荟萃分析，包括2019年12月1日至7月11日之间的WHO Covid-19数据库进行了对控制（非哮喘）组的研究。使用Sidik-Jonkman随机效应汇集患病率和风险比率Meta-Analyses.Findings 5​​.08％的研究（95％CI 6.87-9.30），Covid-19阳性案件中具有哮喘的人们的患病率。用于获得Covid-19的风险比为0.83（95％CI 0.73-0.95，P = 0.01）;1.18（95％CI 0.98-1.42，P = 0.08）用于住院;ICU入院1.21（95％CI 0.97-1.51，P = 0.09）;1.06（95％CI 0.82-1.36，p = 0.65）用于通风机使用，0.94（95％CI 0.76-1.17; p = 0.58），用于哮喘的人们的死亡率。大陆分析分析揭示了收购Covid-19，ICU入场，呼吸机使用和死亡风险的显着差异。与非哮喘组相比，诠释了SARS-COV-2感染的风险。 No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America where few studies originate.The risk of being infected with SARS-CoV-2 was reduced compared to the non-asthma group. No significant differences in hospitalisation, ICU admission, ventilator use and mortali were found between groups. ER -